MedTrace Logo

Developing an AI Pharmacy Chatbot for the Population of Hong Kong

NCT07037563 · Status: RECRUITING · Phase: NA · Type: INTERVENTIONAL · Enrollment: 280

Last updated 2025-06-25

No results posted yet for this study

Summary

The primary objective of this study is to is to develop a conversational AI service (chatbot) in Hong Kong to assist patients and caregivers with inquires related to Hospital Authority (HA)-prescribed medications, and to evaluate its effectiveness in answering medication-related questions. The main questions it aims to answer are:

1. How satisfied are the patients and caregivers with this pharmacy chatbot?
2. How will the pharmacy chatbot impact eligible patients or caregivers on their (or the patient they are caring for) medication adherence, knowledge, and the consultation time with HA pharmacists?

There will be an intervention group and a control group:

1. The intervention group will be invited to use the AI Pharmacy Chatbot online for 7 days through WhatsApp, a commonly used social media platform in Hong Kong. They can inquire about their medications prescribed under HA and get instant, validated answers from the chatbot.
2. The control group will not use the chatbot during the intervention period.

To evaluate the chatbot's usability, researchers will measure patient satisfaction through usability questionnaires issued to the intervention group after their intervention period. Differences in medication adherence, medication knowledge, and HA pharmacist consultation time will also be measured between the intervention and control groups after the intervention period, to determine the chatbot's impact.

Conditions

  • Hyperglycaemia
  • Hypertension
  • Hyperlipidaemia
  • Artificial Intelligence (AI)

Interventions

OTHER

An AI pharmacy chatbot offering information related to HA-prescribed medication for hyperglycaemia, hypertension, and hyperlipidaemia

It is a chatbot for HA-prescribed medication used for treating hyperglycaemia, hypertension, and hyperlipidaemia, available through WhatsApp. All the responses will be extracted from a database, in which the content was obtained from and validated by pharmacists from the Chief Pharmacist's Office of the Hospital Authority in Hong Kong. The intervention period will last for 7 days.

Sponsors & Collaborators

  • Laboratory of Data Discovery for Health

    collaborator UNKNOWN

  • Hospital Authority, Hong Kong

    collaborator OTHER_GOV

  • The University of Hong Kong

    lead OTHER

Principal Investigators

  • Joseph Wu, PhD · The University of Hong Kong

Study Design

Allocation
RANDOMIZED
Purpose
HEALTH_SERVICES_RESEARCH
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2025-06-30
Primary Completion
2026-10-31
Completion
2026-10-31

Countries

  • Hong Kong

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT07037563 on ClinicalTrials.gov